IMPACT OF MOLECULAR MARKERS ON THE OUTCOME OF ACUTE MYELOID LEUKEMIA WITH INTERMEDIATE-RISK CYTOGENETICS

被引：0
|
作者：
Hoyos, M. [1 ]
Brunet, S. [2 ]
Tormo, M. [2 ]
Ribera, J. M. [2 ]
Nomdedeu, J. [2 ]
Esteve, J. [2 ]
Llorente, A. [2 ]
Gallardo, D. [2 ]
Queipo de Llano, M. P. [2 ]
Duarte, R. [2 ]
Heras, I. [2 ]
Besalduch, J. [2 ]
Bargay, J. [2 ]
Marti, J. M. [2 ]
Pedro, C. [2 ]
Gonzalez, J. [2 ]
Font, L. [2 ]
Pratcorona, M. [2 ]
Oriol, A. [2 ]
Sierra, J. [2 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[2] CET LAM Cooperat Grp, Barcelona, Spain
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0640
引用
收藏
页码：268 / 269
页数：2
相关论文
共 50 条
  • [1] Impact of race on outcomes in intermediate-risk acute myeloid leukemia
    Ivy Elizabeth Abraham
    Anand Ashwin Patel
    Heidy Wang
    John Patrick Galvin
    Olga Frankfurt
    Li Liu
    Irum Khan
    Cancer Causes & Control, 2021, 32 : 705 - 712
  • [2] Impact of race on outcomes in intermediate-risk acute myeloid leukemia
    Abraham, Ivy Elizabeth
    Patel, Anand Ashwin
    Wang, Heidy
    Galvin, John Patrick
    Frankfurt, Olga
    Liu, Li
    Khan, Irum
    CANCER CAUSES & CONTROL, 2021, 32 (07) : 705 - 712
  • [3] 5′-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics
    Diaz-Santa, Johana
    Rodriguez-Romanos, Rocio
    Coll, Rosa
    Osca, Gemma
    Pratcorona, Marta
    Gonzalez-Bartulos, Marta
    Garrido, Ana
    Angona, Anna
    Talarn, Carme
    Tormo, Mar
    Arnan, Montserrat
    Vives, Susanna
    Salamero, Olga
    Tuset, Esperanza
    Lloveras, Natalia
    Diez, Isabel
    Zamora, Lurdes
    Bargay, Joan
    Sampol, Antonia
    Cruz, David
    Vila, Jordi
    Sitges, Marta
    Garcia, Antoni
    Vall-Llovera, Ferran
    Esteve, Jordi
    Sierra, Jorge
    Gallardo, David
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (06) : 755 - 764
  • [4] Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes
    Pleyer, Lisa
    Burgstaller, Sonja
    Stauder, Reinhard
    Girschikofsky, Michael
    Linkesch, Werner
    Pfeilstoecker, Michael
    Autzinger, Eva Maria
    Tinchon, Christoph
    Sliwa, Thamer
    Lang, Alois
    Sperr, Wolfgang R.
    Geissler, Dietmar
    Krippl, Peter
    Voskova, Daniela
    Rossmann, Dieter H.
    Schlick, Konstantin
    Thaler, Josef
    Halter, Britta
    Machherndl-Spandl, Sigrid
    Theiler, Georg
    Valent, Peter
    Eckmuellner, Otto
    Greil, Richard
    BLOOD, 2014, 124 (21)
  • [5] Molecular markers predicting clinical outcome in patients with intermediate-risk acute myeloid leukemia receiving autologous stem cell transplantation.
    Esteve, Jordi
    Kalko, Susana
    Torrebadell, Montserrat
    Camos, Mireia
    Jares, Pedro
    Rozman, Maria
    Pratcorona, Marta
    Brunet, Salut
    Nomdedeu, Josep
    Carrio, Ana
    Costa, Dolors
    Montserrat, Emili
    BLOOD, 2007, 110 (11) : 186A - 186A
  • [6] Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial
    Bouvier, Anne
    Hamel, Jean-Francois
    Delaunay, Jacques
    Delabesse, Eric
    Dumas, Pierre-Yves
    Ledoux, Marie-Pierre
    Peterlin, Pierre
    Luquet, Isabelle
    Roth Guepin, Gabrielle
    Bulabois, Claude Eric
    Gallego Hernanz, Maria Pilar
    Guillerm, Gaelle
    Guieze, Romain
    Hicheri, Yosr
    Simand, Celestine
    Himberlin, Chantal
    Hunault-Berger, Mathilde
    Bernard, Marc
    Jourdan, Eric
    Caillot, Denis
    Dorvaux, Veronique
    Tavernier, Emmanuelle
    Daguindau, Etienne
    Banos, Anne
    Ojeda-Uribe, Mario
    Gyan, Emmanuel
    Alexis, Magda
    Marolleau, Jean-Pierre
    Turlure, Pascal
    Bouscary, Didier
    Humbrecht, Catherine
    Zerazhi, Hacene
    Bene, Marie-Christine
    Pigneux, Arnaud
    Carre, Martin
    Ifrah, Norbert
    Blanchet, Odile
    Vey, Norbert
    Recher, Christian
    Cornillet-Lefebvre, Pascale
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (01) : 111 - 121
  • [7] Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics.
    Pratcorona, Marta
    Camos, Mireia
    Torrebadell, Montserrat
    Rozman, Maria
    Carrio, Ana
    Costa, Dolors
    Valera, Alexandra
    Campo, Elias
    Montserrat, Emili
    Esteve, Jordi
    BLOOD, 2008, 112 (11) : 875 - 876
  • [8] The Impact of Allogeneic Hematopoietic Stem-Cell Transplantation on Outcome of the Patients with Intermediate-Risk Acute Myeloid Leukemia
    Wang, Ying
    Wei, Hui
    Lin, Dong
    Zhou, Chunlin
    Liu, Bingcheng
    Qiu, Shaowei
    Gong, Benfa
    Zhang, Guangji
    Liu, Kaiqi
    Wei, Shuning
    Liu, Yuntao
    Gong, Xiaoyuan
    Zhao, Xingli
    Li, Yan
    Gu, Runxia
    Mi, Yingchang
    Wang, Jianxiang
    BLOOD, 2016, 128 (22)
  • [9] Intermediate-risk acute myeloid leukemia therapy: current and future
    Doehner, Konstanze
    Paschka, Peter
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 34 - 43
  • [10] TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
    Chou, Wen-Chien
    Chou, Sheng-Chieh
    Liu, Chieh-Yu
    Chen, Chien-Yuan
    Hou, Hsin-An
    Kuo, Yuan-Yeh
    Lee, Ming-Cheng
    Ko, Bor-Sheng
    Tang, Jih-Luh
    Yao, Ming
    Tsay, Woei
    Wu, Shang-Ju
    Huang, Shang-Yi
    Hsu, Szu-Chun
    Chen, Yao-Chang
    Chang, Yi-Chang
    Kuo, Yi-Yi
    Kuo, Kuan-Ting
    Lee, Fen-Yu
    Liu, Ming-Chi
    Liu, Chia-Wen
    Tseng, Mei-Hsuan
    Huang, Chi-Fei
    Tien, Hwei-Fang
    BLOOD, 2011, 118 (14) : 3803 - 3810
12345